Breakthrough Research Uncovers Early Developmental Links to Spinal Muscular Atrophy
Researchers from DZNE and Dresden University of Technology have made groundbreaking discoveries about spinal muscular atrophy (SMA), linking the disease to embryonic development abnormalities. Published in Cell Reports Medicine, their study emphasizes the need for early intervention and offers hope for new therapeutic strategies targeting SMA from its origins, potentially transforming treatment approaches for this debilitating neurological condition.
Study Links Spinal Muscular Atrophy to Increased Risk of Fatty Liver Disease
Recent international study reveals a concerning link between Spinal Muscular Atrophy (SMA) and an increased risk of fatty liver disease. SMA patients may face liver dysfunction due to reduced SMN protein levels, leading to fat accumulation and inflammation. Editing faulty genes to boost SMN production could reverse liver issues in SMA patients, highlighting the importance of monitoring and addressing liver health in this population.
Conditional Approval Granted to Takeda’s Qdenga Dengue Vaccine
The Drug Control Authority has granted conditional approval to Takeda’s Qdenga dengue vaccine, recommended by the World Health Organization to combat the alarming spike in dengue cases. With a reported 86.3% increase in cases and 100 deaths in 2023, the approval of the vaccine is a crucial development in addressing the public health menace of dengue fever.